Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Aeglea BioTherapeutics, Inc. | Director | Stock Option (right to buy) | 1.95M | Jun 22, 2023 | Direct | ||
Gossamer Bio, Inc. | Director | Non-qualified stock option (Right to Buy) | 115K | Jun 6, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
GOSS | Gossamer Bio, Inc. | Jun 6, 2024 | 1 | $0 | 4 | Jun 6, 2024 | Director |
AGLE | Aeglea BioTherapeutics, Inc. | Jun 22, 2023 | 1 | $0 | 4 | Jun 30, 2023 | Director |
GOSS | Gossamer Bio, Inc. | Jun 8, 2023 | 1 | $0 | 4 | Jun 9, 2023 | Director |
GOSS | Gossamer Bio, Inc. | Jun 9, 2022 | 1 | $0 | 4 | Jul 15, 2022 | Director |
AGLE | Aeglea BioTherapeutics, Inc. | Jun 7, 2022 | 1 | $0 | 4 | Jun 9, 2022 | Director |
GOSS | Gossamer Bio, Inc. | Jun 9, 2021 | 1 | $0 | 4 | Jun 10, 2021 | Director |
AGLE | Aeglea BioTherapeutics, Inc. | Jun 8, 2021 | 1 | $0 | 4 | Jun 9, 2021 | Director |